ASCO Updates Mesothelioma Guidelines: Immunotherapy Doubles 5-Year Survival to 14% as Standard of Care
David Foster
April 2, 2026
ASCO's 2025 guideline update makes dual immunotherapy the standard first-line treatment for mesothelioma. Review survival data, eligibility, and next steps.